211 related articles for article (PubMed ID: 29190892)
1. LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway.
Zhu QN; Wang G; Guo Y; Peng Y; Zhang R; Deng JL; Li ZX; Zhu YS
Oncotarget; 2017 Nov; 8(54):91990-92003. PubMed ID: 29190892
[TBL] [Abstract][Full Text] [Related]
2. H19 lncRNA mediates 17β-estradiol-induced cell proliferation in MCF-7 breast cancer cells.
Sun H; Wang G; Peng Y; Zeng Y; Zhu QN; Li TL; Cai JQ; Zhou HH; Zhu YS
Oncol Rep; 2015 Jun; 33(6):3045-52. PubMed ID: 25846769
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1.
Wang Y; Zhou P; Li P; Yang F; Gao XQ
Bioengineered; 2020 Dec; 11(1):536-546. PubMed ID: 32345117
[TBL] [Abstract][Full Text] [Related]
4. Exosome-mediated transfer of long noncoding RNA H19 induces doxorubicin resistance in breast cancer.
Wang X; Pei X; Guo G; Qian X; Dou D; Zhang Z; Xu X; Duan X
J Cell Physiol; 2020 Oct; 235(10):6896-6904. PubMed ID: 31994191
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
Han J; Han B; Wu X; Hao J; Dong X; Shen Q; Pang H
Toxicol Appl Pharmacol; 2018 Nov; 359():55-61. PubMed ID: 30244121
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide profiling of long non-coding RNA expression patterns in anthracycline-resistant breast cancer cells.
He DX; Zhang GY; Gu XT; Mao AQ; Lu CX; Jin J; Liu DQ; Ma X
Int J Oncol; 2016 Oct; 49(4):1695-1703. PubMed ID: 27633960
[TBL] [Abstract][Full Text] [Related]
7. LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1.
Kun-Peng Z; Xiao-Long M; Chun-Lin Z
Oncotarget; 2017 Sep; 8(42):71881-71893. PubMed ID: 29069754
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA H19 mediates N-acetyltransferase 1 gene methylation in the development of tamoxifen resistance in breast cancer.
Sun H; Wang G; Cai J; Wei X; Zeng Y; Peng Y; Zhuang J
Exp Ther Med; 2022 Jan; 23(1):12. PubMed ID: 34815764
[TBL] [Abstract][Full Text] [Related]
9. The silencing of LncRNA-H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial-mesenchymal transition via the Wnt/β-Catenin pathway.
Jia L; Tian Y; Chen Y; Zhang G
Onco Targets Ther; 2018; 11():313-321. PubMed ID: 29391808
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process.
Gao H; Hao G; Sun Y; Li L; Wang Y
Onco Targets Ther; 2018; 11():8001-8012. PubMed ID: 30519041
[TBL] [Abstract][Full Text] [Related]
11. The role of H19 lncRNA in conferring chemoresistance in cancer cells.
Ghafouri-Fard S; Shoorei H; Bahroudi Z; Abak A; Taheri M
Biomed Pharmacother; 2021 Jun; 138():111447. PubMed ID: 33667788
[TBL] [Abstract][Full Text] [Related]
12. LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma.
Liu Z; Zhang H
Oncotarget; 2017 Sep; 8(38):64273-64282. PubMed ID: 28969069
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis.
Zhu KP; Zhang CL; Shen GQ; Zhu ZS
Int J Clin Exp Pathol; 2015; 8(8):8754-73. PubMed ID: 26464619
[TBL] [Abstract][Full Text] [Related]
14. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells.
Tsang WP; Kwok TT
Oncogene; 2007 Jul; 26(33):4877-81. PubMed ID: 17297456
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
16. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
17. LncRNA NONHSAT141924 promotes paclitaxel chemotherapy resistance through p-CREB/Bcl-2 apoptosis signaling pathway in breast cancer.
Gu M; Zheng W; Zhang M; Dong X; Zhao Y; Wang S; Jiang H; Zheng X
J Cancer; 2020; 11(12):3645-3654. PubMed ID: 32284761
[TBL] [Abstract][Full Text] [Related]
18. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
[TBL] [Abstract][Full Text] [Related]
19. Identification of long non-coding RNA signature for paclitaxel-resistant patients with advanced ovarian cancer.
Wang L; Hu Y; Xiang X; Qu K; Teng Y
Oncotarget; 2017 Sep; 8(38):64191-64202. PubMed ID: 28969062
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
